Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Acute Kidney InjuryIschemia Reperfusion Injury
Interventions
DRUG

Valproic acid

Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration

DRUG

Isotonic saline solution

Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration

Trial Locations (4)

75390

University of Texas Southwest, Dallas

77030

Houston Methodist Specialty and Transplant Hospital, Houston

80045

University of Colorado - Denver, Denver

94143

University of California San Francisco, San Francisco

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Clinipace Worldwide

INDUSTRY

lead

Westat

OTHER